137 related articles for article (PubMed ID: 21246556)
1. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery.
Abdelkader H; Ismail S; Kamal A; Alany RG
J Pharm Sci; 2011 May; 100(5):1833-46. PubMed ID: 21246556
[TBL] [Abstract][Full Text] [Related]
2. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization.
Abdelkader H; Ismail S; Kamal A; Alany RG
Pharmazie; 2010 Nov; 65(11):811-7. PubMed ID: 21155387
[TBL] [Abstract][Full Text] [Related]
3. Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models.
Abdelkader H; Ismail S; Hussein A; Wu Z; Al-Kassas R; Alany RG
Int J Pharm; 2012 Aug; 432(1-2):1-10. PubMed ID: 22575752
[TBL] [Abstract][Full Text] [Related]
4. Niosomes and discomes for ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading properties and photo-protective effects.
Abdelkader H; Wu Z; Al-Kassas R; Alany RG
Int J Pharm; 2012 Aug; 433(1-2):142-8. PubMed ID: 22595640
[TBL] [Abstract][Full Text] [Related]
5. Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride.
Abdelbary A; Salem HF; Khallaf RA; Ali AM
Pharm Dev Technol; 2017 May; 22(3):409-417. PubMed ID: 27476543
[TBL] [Abstract][Full Text] [Related]
6. Multivesicular liposomes for sustained release of naltrexone hydrochloride: design, characterization and in vitro/in vivo evaluation.
Sun L; Wang T; Gao L; Quan D; Feng D
Pharm Dev Technol; 2013; 18(4):828-33. PubMed ID: 22759074
[TBL] [Abstract][Full Text] [Related]
7. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride.
Hasan AA
Pharm Dev Technol; 2014 Sep; 19(6):748-54. PubMed ID: 23964893
[TBL] [Abstract][Full Text] [Related]
8. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies.
Abdelkader H; Pierscionek B; Alany RG
Int J Pharm; 2014 Dec; 477(1-2):631-42. PubMed ID: 25445974
[TBL] [Abstract][Full Text] [Related]
9. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection.
Li Q; Li Z; Zeng W; Ge S; Lu H; Wu C; Ge L; Liang D; Xu Y
Eur J Pharm Sci; 2014 Oct; 62():115-23. PubMed ID: 24905830
[TBL] [Abstract][Full Text] [Related]
10. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation.
Aggarwal D; Garg A; Kaur IP
J Pharm Pharmacol; 2004 Dec; 56(12):1509-17. PubMed ID: 15563757
[TBL] [Abstract][Full Text] [Related]
11. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
Mokhtar M; Sammour OA; Hammad MA; Megrab NA
Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
[TBL] [Abstract][Full Text] [Related]
12. Effect of formulation compositions on niosomal preparations.
Chaw CS; Kim KY
Pharm Dev Technol; 2013; 18(3):667-72. PubMed ID: 22468904
[TBL] [Abstract][Full Text] [Related]
13. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone.
Zagon IS; Sassani JW; McLaughlin PJ
Cornea; 2006 Aug; 25(7):821-9. PubMed ID: 17068460
[TBL] [Abstract][Full Text] [Related]
14. An electron spin resonance study of non-ionic surfactant vesicles (niosomes).
Yeom S; Shin BS; Han S
Chem Phys Lipids; 2014 Jul; 181():83-9. PubMed ID: 24721595
[TBL] [Abstract][Full Text] [Related]
15. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol.
Devaraj GN; Parakh SR; Devraj R; Apte SS; Rao BR; Rambhau D
J Colloid Interface Sci; 2002 Jul; 251(2):360-5. PubMed ID: 16290741
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Guinedi AS; Mortada ND; Mansour S; Hathout RM
Int J Pharm; 2005 Dec; 306(1-2):71-82. PubMed ID: 16263229
[TBL] [Abstract][Full Text] [Related]
17. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes.
Arunothayanun P; Turton JA; Uchegbu IF; Florence AT
J Pharm Sci; 1999 Jan; 88(1):34-8. PubMed ID: 9874699
[TBL] [Abstract][Full Text] [Related]
18. Sorbitan ester niosomes for topical delivery of rofecoxib.
Das MK; Palei NN
Indian J Exp Biol; 2011 Jun; 49(6):438-45. PubMed ID: 21702223
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo studies for the passive transdermal delivery of low-dose naltrexone from a cream; detection of naltrexone and its active metabolite, 6β-naltrexol, using a novel LC Q-ToF MS assay.
Dodou K; Armstrong A; Kelly I; Wilkinson S; Carr K; Shattock P; Whiteley P
Pharm Dev Technol; 2015; 20(6):694-701. PubMed ID: 24785567
[TBL] [Abstract][Full Text] [Related]
20. PEGylated non-ionic surfactant vesicles as drug delivery systems for Gambogenic acid.
Lin T; Fang Q; Peng D; Huang X; Zhu T; Luo Q; Zhou K; Chen W
Drug Deliv; 2013; 20(7):277-84. PubMed ID: 24044645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
